Cracking The Code: Understanding Analyst Reviews For ADMA Biologics
Portfolio Pulse from Benzinga Insights
ADMA Biologics (NASDAQ:ADMA) received mixed analyst ratings in the latest quarter, with 4 analysts offering views. The average 12-month price target is $6.5, up from $6.00, with a high of $9.00 and a low of $5.00. Analysts from Mizuho and HC Wainwright & Co. raised their price targets, while Cantor Fitzgerald maintained its rating. ADMA Biologics is a biopharmaceutical company focusing on plasma-derived biologics for immunodeficient patients. The company's financials show a revenue growth of 63.72%, a net margin of 3.81%, ROE of 1.72%, ROA of 0.74%, and a debt-to-equity ratio of 1.01.
January 22, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics has received mixed analyst ratings with an increased average price target of $6.5. The company's strong financial performance indicators may positively influence investor sentiment.
The increase in the average price target and positive financial indicators such as revenue growth and net margin suggest a bullish outlook for ADMA Biologics in the short term. Analyst upgrades typically lead to positive investor sentiment, which can drive the stock price up.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100